1. < Cedars Sinai DoM

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer

By sjmartinez • June 30, 2023

Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2023 Jun 30. doi: 10.2217/fon-2023-0188. Epub ahead of print. PMID: 37387213.

Tags: antibody-drug conjugate (ADC), Cedars Sinai DoM, datopotamab deruxtecan (Dato-DXd), Hematology/Oncology, HR-positive/HER2-negative, inoperable breast cancer, metastatic breast cancer, Publications, Trophoblast cell surface antigen 2 (TROP2)

Related Posts

Immunomodulatory Nanoparticles Enable Combination Therapies To Enhance Disease Prevention and Flare Control in Rheumatoid Arthritis

Johnson WT, Wilkinson EL, Iyer N, Dolmat M, Bollmann M, Dada N, Wei X, Yang S, Zhang T, Yoo G, Bernardo M, Price M, Frame[...]

All-in-One Cardiac MRI: Unified Non-Contrast-enhanced and Contrast-enhanced Imaging for a Continuous-Acquisition Examination

Mao X, Chen Z, Hu Z, Lee HL, Kwan AC, Cokic I, Cao T, Han F, Xie Y, Li D, Christodoulou AG. All-in-One Cardiac MRI:[...]

Minimum standards for training in colorectal endoscopic mucosal resection among advanced endoscopy trainees

Yang D, Robalino Gonzaga E, Hasan MK, Trindade AJ, Radlinski M, Burbridge RA, Mosko J, Taunk P, Jawaid S, Othman MO, Diehl DL, Khara HS,[...]